Read by QxMD icon Read

APRI, chronic liver disease , cirrhosis

Anna Weis, Louise Marquart, Diego A Calvopina, Berit Genz, Grant A Ramm, Richard Skoien
Early diagnosis of cirrhosis and hepatocellular carcinoma (HCC) due to chronic Hepatitis C (CHC) remain clinical priorities. In this pilot study, we assessed serum microRNA (miRNA) expression to distinguish cirrhosis and HCC, alone and in combination with the aminotransferase-to-platelet ratio (APRI), Fibrosis 4 (FIB-4), and alpha-fetoprotein (AFP). Sixty CHC patients were subdivided into 3 cohorts: Mild disease (fibrosis stage F0-2; n = 20); cirrhosis ( n = 20); and cirrhosis with HCC ( n = 20). Circulating miRNA signatures were determined using a liver-specific real-time quantitative reverse transcription PCR (qRT-PCR) microarray assessing 372 miRNAs simultaneously...
February 17, 2019: International Journal of Molecular Sciences
Lung-Yi Mak, Danny Ka-Ho Wong, Wai-Kay Seto, Qin Ning, Ka-Shing Cheung, James Fung, Ching-Lung Lai, Man-Fung Yuen
BACKGROUND AND AIM: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases. We aimed to evaluate its role in assessment of liver fibrosis in chronic hepatitis B infection (CHB) with reference to liver stiffness measurement (LSM). METHODS: CHB patients with LSM by transient elastography technology and retrievable serum samples were recruited. Ten-year re-assessments of LSM and M2BPGi were repeated in a patient subgroup...
January 22, 2019: Hepatology International
Monica A Konerman, Lauren A Beste, Tony Van, Boang Liu, Xuefei Zhang, Ji Zhu, Sameer D Saini, Grace L Su, Brahmajee K Nallamothu, George N Ioannou, Akbar K Waljee
BACKGROUND: Machine learning (ML) algorithms provide effective ways to build prediction models using longitudinal information given their capacity to incorporate numerous predictor variables without compromising the accuracy of the risk prediction. Clinical risk prediction models in chronic hepatitis C virus (CHC) can be challenging due to non-linear nature of disease progression. We developed and compared two ML algorithms to predict cirrhosis development in a large CHC-infected cohort using longitudinal data...
2019: PloS One
Sabela Lens, Ferran Torres, Martin Bonacci, Concepció Bartres, Anna Pocurull, Zoe Mariño, María-Carlota Londoño, Sergio Rodríguez-Tajes, Xavier Forns
BACKGROUND AND AIMS: In some areas of the world, antiviral therapy for chronic hepatitis C (CHC) is not available for all patients. The optimal interval for liver stiffness measures (LSM) and noninvasive scores to assess fibrosis progression has not been studied. We evaluated the usefulness of consecutive LSM, APRI, FIB-4 and Forns scores to predict disease progression. METHODS: Patients with CHC and at least two annual LSM within 3 years were followed for a minimum of 5 years...
November 29, 2018: Digestive and Liver Disease
Ji Hyun Kim, Minjong Lee, Seung Woo Park, Myungho Kang, Minjeong Kim, Sang Hoon Lee, Tae Suk Kim, Jin Myung Park, Dae Hee Choi
Recently, modified fibrosis-4 index (mFIB-4) and the easy liver fibrosis test (eLIFT) were developed for predicting liver fibrosis in chronic liver disease patients. We evaluated whether the 2 tests can predict hepatocellular carcinoma (HCC) risk in alcoholic liver cirrhosis (ALC) patients.A retrospective cohort of 924 ALC patients was assessed for HCC development. Four non-invasive serum biomarkers, mFIB-4, the eLIFT score, fibrosis-4 index (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) were tested using time-dependent analysis of areas under receiver operating characteristic curve (AUROC), DeLong, and log-rank tests...
November 2018: Medicine (Baltimore)
Jing Meng, Hongqin Xu, Xu Liu, Ruihong Wu, Junqi Niu
Primary biliary cholangitis (PBC) is a chronic disease that is increasingly being recognized in recent years. In this study, we sought to identify noninvasive markers of the severity of cirrhosis in patients with PBC based on routinely investigated laboratory parameters.Ninety-four patients with histologically-confirmed PBC based on liver biopsy performed between January 2013 and December 2017 at the First Hospital of Jilin University were divided into 2 groups: early-stage cirrhosis (fibrosis stage F1 and F2; n = 74) and advanced-stage cirrhosis (fibrosis stage F3 and F4; n = 20)...
November 2018: Medicine (Baltimore)
Zohair Ahmed, Jinma Ren, Adam Gonzalez, Umair Ahmed, Saqib Walayat, Daniel K Martin, Harsha Moole, Sherri Yong, Sean Koppe, Sonu Dhillon
Aim: The purpose of this study was to create and validate a novel serological diagnostic index to predict cirrhosis of all etiologies. Methods: This was a retrospective observational study of 771 patients, age >18 years, who underwent a liver biopsy. The stage of fibrosis and routine laboratory values were recorded. The data were randomly separated into 2 datasets (training 50% and testing 50%). A stepwise logistic regression model was used to develop the novel index...
2018: Hepatic Medicine: Evidence and Research
Edoardo G Giannini, Mattia Crespi, Mariagiulia Demarzo, Giorgia Bodini, Manuele Furnari, Elisa Marabotto, Francesco Torre, Patrizia Zentilin, Vincenzo Savarino
BACKGROUND: The outcome of patients with chronic hepatitis C virus infection (HCV) and advanced, compensated liver disease after sustained virological response (SVR) to direct-acting antivirals (DAAs) has not yet been completely depicted. We aimed to assess the clinical, biochemical, and instrumental outcome of patients with advanced, compensated chronic HCV-related liver disease with DAAs-induced SVR to DAAs and who had at least 1-year follow-up. MATERIALS AND METHODS: Fifty-two patients with cirrhosis (n=27) and fibrosis stage F3 (n=25) followed-up for a median of 60 weeks after successful DAAs treatment were included...
November 26, 2018: European Journal of Clinical Investigation
Gaurav Garg, Vinod K Dixit, Sunit K Shukla, Sudhir K Singh, Shivam Sachan, Anurag Tiwari, Vinod K Yadav, Dawesh P Yadav
Background/aims: Treatment of chronic hepatitis C infection with direct-acting antiviral (DAA) drugs has been highly effective, but data regarding benefit in advanced liver disease is relatively scarce in Indian patients. The aim of this study was to determine the effects of DAA in patients with HCV related cirrhosis (compensated/decompensated) who achieved sustained virological response post-therapy at 12 weeks (SVR12). Methods: Sixty-three patients with HCV related cirrhosis treated with sofosbuvir based regimen were evaluated...
September 2018: Journal of Clinical and Experimental Hepatology
Ya-Chao Tao, Rong Deng, Meng-Lan Wang, Duo-Duo Lv, Man Yuan, Yong-Hong Wang, En-Qiang Chen, Hong Tang
BACKGROUND: Chronic hepatitis C virus (HCV) genotype (GT) 3 infection with advanced liver disease has emerged as a challenging to treat by direct-acting antivirals (DAAs), but the efficacy of DAAs in Chinese HCV-GT3 patients is rarely reported. This study aimed to analyze the efficacy of sofosbuvir (SOF)-based regimens in Chinese patients with HCV-GT3 and compensated liver disease. METHODS: This was a registered retrospective study. All patients had completed at least 12 weeks SOF-based regimens therapy (with or without RBV), and were followed up for at least 24 weeks after therapy discontinuation...
October 1, 2018: Virology Journal
Matthias Buechter, Jonas Thimm, Hideo A Baba, Stefanie Bertram, Katharina Willuweit, Guido Gerken, Alisan Kahraman
AIM: To assess the diagnostic accuracy of liver maximum capacity (LiMAx®) test compared to transient elastography (TE) and serum biomarkers for the noninvasive detection of different stages of liver fibrosis and cirrhosis. PATIENTS AND METHODS: We retrospectively correlated LiMAx®, TE, aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), AST-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4) score with histological specimens in 102 patients with chronic liver disease (CLD) who underwent liver biopsy (either percutaneously or via mini-laparoscopy) at the University Clinic of Essen between 10/2016 and 12/2017...
October 2, 2018: Digestion
Michinori Matsumoto, Shigeki Wakiyama, Hiroaki Shiba, Koichiro Haruki, Yasuro Futagawa, Yuichi Ishida, Takeyuki Misawa, Katsuhiko Yanaga
Liver function is a major prognostic factor following hepatic resection for hepatocellular carcinoma (HCC), which is well correlated with the degree of fibrosis. On the other hand, the presence of liver cirrhosis itself leads to a higher incidence of HCC than chronic hepatitis. Therefore, preoperative noninvasive markers of fibrosis are important for the assessment of prognosis for treatment of HCC. The present study aimed to analyze whether aspartate aminotransferase to platelet ratio index (APRI) could predict prognosis following hepatic resection for HCC...
October 2018: Molecular and Clinical Oncology
Chien-Lin Chen, Wei-Chuan Chang, Chih-Hsun Yi, Jui-Sheng Hung, Tso-Tsai Liu, Wei-Yi Lei, Ching-Sheng Hsu
BACKGROUND/PURPOSE: Although coffee consumption has been associated with decreased risk of liver fibrosis progression, cirrhosis or hepatocellular carcinoma in patients with HCV infection or fatty liver diseases, its effect on hepatitis B patients remains unclear. We aimed to examine the effect of coffee consumption on liver fibrosis progression and cirrhosis-related complications in patients with chronic HBV infection. METHODS: Coffee consumption was assessed in 2604 participants who were previously recruited from a population-based GERD survey...
August 16, 2018: Journal of the Formosan Medical Association
H Li, T Yan, Z Zhu, Z W Bao, T M Xu, J Xie, S Q Zheng, M M Cui, L G Liu
Objective: To study the correlation between the level of serum Chitinase-3-like protein 1 (CHI3L1) and the significant liver fibrosis and liver cirrhosis in patients with chronic liver disease, and to evaluate its diagnostic value. Methods: 165 patients with chronic liver disease were selected, liver histopathological examination was performed to detect serum CHI3L1 concentration. Four indexes of hepatic fibrosis (type III procollagen, collagen IV, laminin, hyaluronic acid), aspartate aminotransferase/platelet ratio index (APRI) and FIB-4 (fibrosis- 4) scores were based on the pathological findings of liver biopsy and compared the advantages and disadvantages of serum CHI3L1 with other methods for the diagnosis of hepatic fibrosis and liver cirrhosis...
May 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
F M Lu, Y Zhang
Liver cirrhosis is the end-stage change of chronic liver diseases with various causative factors. The accurate diagnosis of liver cirrhosis in an early stage is very important for the timely treatment and prognosis of patients. A liver biopsy test is the gold standard for the diagnosis of liver cirrhosis; but its use is limited in clinical practices due to its invasive nature. The conventional non-invasive measures (APRI, FIB-4 and LSM) for diagnosis of liver cirrhosis could not fulfill the needs. Therefore, finding a new serological marker of liver cirrhosis has become a research hotspot...
May 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Geórgia Nascimento Saraiva, Natalia Fonseca do Rosário, Thalia Medeiros, Paulo Emílio Côrrea Leite, Gilmar de Souza Lacerda, Thaís Guaraná de Andrade, Elzinandes Leal de Azeredo, Petronela Ancuta, Jorge Reis Almeida, Analúcia Rampazzo Xavier, Andrea Alice Silva
This study aimed at analyzing circulating levels of inflammatory and profibrogenic cytokines in patients with hepatitis C virus (HCV) chronic infection undergoing therapy with direct-acting antiviral agents (DAA) and correlating these immune biomarkers with liver disease status. We studied 88 Brazilian monoinfected chronic hepatitis C patients receiving interferon- (IFN-) free sofosbuvir-based regimens for 12 or 24 weeks, followed-up before therapy initiation and three months after the end of treatment. Liver disease was determined by transient elastography, in addition to APRI and FIB-4 indexes...
2018: Mediators of Inflammation
Enoka S Gonsalkorala, Mary D Cannon, Tiong Yeng Lim, Leonie Penna, Catherine Willliamson, Michael A Heneghan
OBJECTIVES: Rates of pregnancy in women with cirrhosis are increasing. Risk of hepatic decompensation during pregnancy, therefore, merits tailored obstetric and hepatology care. Prognostic markers that determine pregnancy outcomes are lacking. METHODS: Medical records of women who attended hepatology clinic at King's College Hospital with chronic liver disease (CLD) who became pregnant from 1983 to 2017 were reviewed. Information on demographics, clinical history, serology, and outcome of pregnancy was collected...
February 2019: American Journal of Gastroenterology
Ira Shah, Nikita Madgum
INTRODUCTION AND AIM: Neonatal cholestasis constitutes for 19 to 33% of all chronic liver disease in India. Cholestasis leads to fibrosis of liver and ultimately cirrhosis. There are various methods of diagnosis of fibrosis of liver like fibroscan, APRI index, FIB-4, fibro index, forns index, heap score, magnetic elastography. Here we are comparing APRI index with METAVIR index in patients with neonatal cholestasis without biliary atresia and determining whether APRI index can be used as a tool to determine fibrosis in these patients...
July 2018: Annals of Hepatology
Xiaojuan Wu, Zhenzhen Su, Bei Cai, Lin Yan, Yamei Li, Weihua Feng, Lanlan Wang
Follicular helper T cells (TFH) and follicular regulatory T cells (TFR), subsets of T cells, co-regulate the reactions of germinal center (GC) B cells. TFH provide help to the GC response, while the TFR suppress those processes. Nevertheless, the role of circulating TFR (cTFR) and circulating TFH (cTFH) in chronic hepatitis B virus (HBV) infection remains limited. Twenty healthy controls (HCs), 24 patients with chronic hepatitis B (CHB), 23 with HBV-related liver cirrhosis (LC), and 18 with HBV-related hepatocellular carcinoma were enrolled in our study between October 2015 and September 2016...
June 2018: Viral Immunology
X-Z Yang, A-W Gen, J-C Xian, L Xiao
OBJECTIVE: Hepatic fibrosis is a repair response to chronic liver injury. This study evaluated the diagnostic value of various noninvasive indicators for hepatic fibrosis in patients with chronic liver disease. PATIENTS AND METHODS: 95 patients with liver biopsy were enrolled in this study. Routine clinical and laboratory examinations were collected, including age, sex, blood routine, biochemistry, serum fibrosis, and FibroTouch. APRI and FIB4 scores were calculated...
January 2018: European Review for Medical and Pharmacological Sciences
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"